Impact News +++ Stimmrechtsanteile News: paragon GmbH & Co. KGaA (EQS) +++ PARAGON KGAA Aktie +5,92%

ORUKA Aktie

>ORUKA Aktienkurs

24.5 EUR (Tradegate)

Ask: 25 EUR / 81 Stück

Bid: 24 EUR / 100 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ORUKA Aktie über LYNX handeln

Intraday

1 Jahr

>ORUKA Performance

1 Woche: -8,2%

1 Monat: +1,2%

3 Monate: +80,9%

6 Monate: +125,7%

1 Jahr: +14,4%

laufendes Jahr: +36,7%

>ORUKA Aktie

Name:

ORUKA THERAPEUTICS INC.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US6876041087 / A3DPH3

Symbol/ Ticker:

HQ1 (Frankfurt) / ORKA (NASDAQ)

Kürzel:

FRA:HQ1, ETR:HQ1, HQ1:GR, NASDAQ:ORKA

Index:

Webseite:

https://orukatx.com/

Profil:

Oruka Therapeutics, Inc. is a clinical-stage biote..
>Volltext..

Marktkapitalisierung:

1194.17 Mio. EUR

Unternehmenswert:

900.4 Mio. EUR

Umsatz:

EBITDA:

-100.47 Mio. EUR

Nettogewinn:

-86.63 Mio. EUR

Gewinn je Aktie:

-2.06 EUR

Schulden:

1.63 Mio. EUR

Liquide Mittel:

77.78 Mio. EUR

Operativer Cashflow:

-71.97 Mio. EUR

Bargeldquote:

16.65

Umsatzwachstum:

Gewinnwachstum:

-180.33%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ORUKA

Letzte Datenerhebung:

18.12.25

>ORUKA Kennzahlen

Aktien/ Unternehmen:

Aktien: 48.41 Mio. St.

Frei handelbar: 88.14%

Leerverk. Aktien: 11.36%

Rückkaufquote: -14.23%

Mitarbeiter: 28

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 64.86%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 2.86

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -22.01%

Eigenkaprendite: -23.05%

>ORUKA Peer Group

Es sind 599 Aktien bekannt.

>ORUKA Chart & Kurs - NASDAQ

>ORUKA News

11.12.25 - 22:03	Oruka Therapeutics Announces New Board Member and Board Transition (GlobeNewswire EN)
	Appoints accomplished commercial leader Chris Martin to its Board of Directors Appoints accomplished commercial leader Chris Martin to its Board of Directors...

13.11.25 - 06:42	Oruka Therapeutics GAAP EPS of -$0.55 beats by $0.01 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.11.25 - 22:09	Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission...

29.10.25 - 12:03	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire EN)
	MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:...

06.10.25 - 05:57	Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday (Benzinga)
	US stock futures up, focus on Constellation Brands, SkyWater Tech, Aehr Test Systems, Oruka Therapeutics and VCI Global earnings. read more...

03.10.25 - 23:30	Oruka Therapeutics files to sell 39.43M shares of common stock for holders (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.09.25 - 14:54	Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.09.25 - 07:06

Oruka Therapeutics Announces $180 Million Private Placement (GlobeNewswire EN)

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $180 million to the Company, before placement agent fees and offering expenses. The PIPE financing was led by Viking Global Investors, and included participation from both new and existing investors, including Affinity Healthcare Fund, Blackstone Multi-Asset Investing, Commodore Capital, Cormorant Asset Management, Deep Track Capital, Fairmount, Great Point Partners, LLC, Palo Alto Investors, LP, Perceptive Advisors, Surveyor Capital (a Citadel company), Venrock Healthcare Capital Partners, Woodline Partners LP and a leading li...

17.09.25 - 07:03	Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 (GlobeNewswire EN)
	Half-life of approximately 100 days increases likelihood of once-per-year dosing...

11.08.25 - 22:33	Oruka Therapeutics GAAP EPS of -$0.46 beats by $0.02 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.08.25 - 22:06	Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026...

21.07.25 - 13:03	Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September (GlobeNewswire EN)
	IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026...

01.07.25 - 22:18	Oruka Therapeutics announces COO appointment (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.07.25 - 22:03	Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer (GlobeNewswire EN)
	MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the promotion of Laura Sandler to Chief Operating Officer....

21.05.25 - 13:03	Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire EN)
	MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Jefferies Global Health Care Conference in New York, NY:...

20.05.25 - 22:03	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody (GlobeNewswire EN)
	Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025...

14.05.25 - 22:18	Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	Continued operational excellence leading to acceleration of multiple timelines:...

07.03.25 - 14:33	Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting (GlobeNewswire EN)
	Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year...

06.03.25 - 22:12	Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025...

28.02.25 - 05:01	Insiderhandel: Insider kauft Aktien von Oruka Therapeutics im Wert von 173869 USD (Insiderkauf)
	Venrock Healthcare Capital Partners III, L.p. - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-02-13...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer lesen kann, der ist niemals einsam. - Prof. Dr. Walter Jens

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram